Dynavax Technologies - DVAX Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DVAX shares.
View DVAX analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 1 year target prices for Dynavax Technologies' stock. Their DVAX share price forecasts range from $21.00 to $22.00. On average, they anticipate the company's share price to reach $21.50 in the next twelve months. This suggests a possible upside of 81.0% from the stock's current price.
View analysts price targets for DVAX or view top-rated stocks among Wall Street analysts.

Dynavax Technologies' stock was trading at $10.64 at the beginning of 2023. Since then, DVAX stock has increased by 11.7% and is now trading at $11.88.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our DVAX earnings forecast.

Dynavax Technologies Co. (NASDAQ:DVAX) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $0.05 by $0.29. The biopharmaceutical company earned $108.27 million during the quarter, compared to analysts' expectations of $77.30 million. Dynavax Technologies had a trailing twelve-month return on equity of 90.54% and a net margin of 44.35%. During the same period last year, the company posted ($0.15) earnings per share.

13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Chicago Capital LLC (4.59%), Nisa Investment Advisors LLC (0.28%), Congress Asset Management Co. MA (0.16%), New York State Teachers Retirement System (0.11%), New York State Common Retirement Fund (0.11%) and Monarch Partners Asset Management LLC (0.10%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer.
View institutional ownership trends.

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DVAX stock can currently be purchased for approximately $11.88.

Dynavax Technologies (NASDAQ:DVAX) has a market capitalization of $1.52 billion and generates $439.44 million in revenue each year. The biopharmaceutical company earns $76.71 million in net income (profit) each year or $2.07 on an earnings per share basis.

The company employs 311 workers across the globe.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The official website for the company is www.dynavax.com. The biopharmaceutical company can be reached via phone at (510) 848-5100, via email at ir@dynavax.com, or via fax at 510-848-1327.